A Prospective Analysis of the Efficacy of Allosync Expand and Autograft Bone Graft in Open Lumbar Spinal Fusion
Launched by RESEARCH SOURCE · May 10, 2024
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a single site, prospective study with patients selected as study subjects from the Investigator's standard patient population who fulfill the Inclusion/Exclusion Criteria and agree to participate in the study. The study surgery is standard of care, with patients identified as requiring surgery prior to enrollment. The study surgery is lumbar posterior fixation with supplemental posterolateral fusion at from 1 to 3 levels. One side of the posterolateral fusion will be Allosync Expand (utilizing the BMA Angel kit to hydrate) and the other side to autograft bone (control).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. At least 22years of age at the time of consent
- 2. Subject must have a documented diagnosis of spondylolisthesis up to Grade I. and have confirmed back and/or radicular pain with associated spinal stenosis as documented by conditions such as:
- • 1. Instability as defined by \>3mm translation or \>5 degree angulation
- • 2. Osteophyte formation of facet joints or vertebral endplates
- 3. Subject presents with one or more of the following:
- • 1. Radiculopathy
- • 2. Sensory deficit
- • 3. Motor weakness
- • 4. Reflex changes
- • 4. Subject requires lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1).
- • 5. The number of levels decompressed must equal the number of levels fused.
- • 6. Subject must have been unresponsive to conservative care for at least 3 months prior to fusion surgery.
- • 7. Subject must be willing and able to sign an informed consent document.
- • 8. Subject must be willing and able to return for all follow-up visits, agree to participate in postoperative clinical and radiographic evaluations and comply with the required study regimen.
- Exclusion Criteria:
- • 1. Subject has had prior lumbar spine fusion surgery at any level.
- • 2. Subject has greater than grade 1 spondylolisthesis of the lumbar spine.
- • 3. Subject is pregnant or nursing or planning to become pregnant during the two years (24 months) following arthrodesis
- • 4. Subject has an active local or systemic infection.
- • 5. Subject is a prisoner
- • 6. Patient has any condition (including malignancy), that in the opinion of the Investigator, would prohibit the patient from complying with and/or completing the protocol
About Research Source
Research Source is a leading clinical trial sponsor dedicated to advancing medical science through innovative research and development. With a focus on delivering high-quality, evidence-based solutions, Research Source collaborates with a diverse network of healthcare professionals, institutions, and industry partners to conduct rigorous clinical studies across various therapeutic areas. Committed to ethical standards and patient safety, the organization strives to accelerate the discovery of new treatments and improve patient outcomes while ensuring compliance with regulatory requirements. Through its expertise and strategic approach, Research Source aims to contribute significantly to the future of healthcare and the well-being of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Southfield, Michigan, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported